Solifenacin索非那新琥珀酸盐,242478-38-

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Solifenacin Succinate

CAS No. : 242478-38-2

MCE 国际站：Solifenacin Succinate

产品活性：Solifenacin Succinate (YM905) 是毒蕈碱受体 (muscarinic receptor) 拮抗剂，对 M₁，M₂ 和 M₃ 受体的 pK_i 值分别为 7.6、6.9 和 8.0。

研究领域：GPCR/G Protein  |  Neuronal Signaling

作用靶点：mAChR

In Vitro: Solifenacin Succinate (YM905) is a novel muscarinic receptor antagonist with pK_is of 7.6±0.056, 6.9±0.034 and 8.0±0.021 for M1, M2 and M3 receptors, respectively. In murine submandibular gland cells, the antagonistic effects of 100 nM Solifenacin Succinate and oxybutynin on Ca²⁺ mobilization evoked by varying doses of carbachol (CCh) are examined. Solifenacin Succinate does not shift the CCh dose-activation curve in a parallel manner whereas oxybutynin shows insurmountable antagonism. The pK_b values are obtained as 7.4±0.17 for Solifenacin Succinate and 8.8±0.21 for oxybutynin.

In Vivo: Solifenacin Succinate (YM905) reduces bladder responses by 40% at a dose of 210 nmol/kg (0.1 mg/kg) and abolishes them at 2100 nmol/kg (1 mg/kg). In contrast, its inhibitory effects on salivary and cardiac responses are only slight at 630 nmol/kg (0.3 mg/kg), and reach 66% and 49%, respectively, at 2100 nmol/kg (1 mg/kg). At doses of 63 and 210 nmol/kg (0.03 and 0.1 mg/kg), Solifenacin Succinate slightly increases saliva secretion. Solifenacin Succinate (0.01 to 0.3 mg/kg i.v.) dose-dependently increases bladder capacity and voided volume at doses of 0.03 mg/kg i.v. or more, but does not affect residual volume or micturition pressure at any dose tested.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  GPCR/G Protein Compound Library  |  Neuronal Signaling Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  CNS-Penetrant Compound Library  |  Drug Repurposing Compound Library  |  NMPA-Approved Drug Library  |  Orally Active Compound Library  |  Neurotransmitter Receptor Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Anti-Parkinson's Disease Compound Library  |  Neurodegenerative Disease-related Compound Library  |  Mechanoreceptors Compound Library  |  Rare Diseases Drug Library  |  FDA-Approved Anticancer Drug Library  |  Anti-Prostate Cancer Compound Library  |  Heterocyclic Compound Library  |  Off-patent Drug Library  |  Membrane Protein-targeted Compound Library  |  Membrane Receptor-targeted Compound Library  |  Clozapine N-oxide  |  Deschloroclozapine  |  Pilocarpine Hydrochloride  |  Atropine  |  Carbamoylcholine chloride  |  Scopolamine hydrobromide  |  Amitriptyline hydrochloride  |  Olanzapine  |  Methacholine chloride  |  Tiotropium Bromide  |  Xanomeline  |  Mepenzolate bromide  |  Promethazine hydrochloride  |  Propantheline bromide  |  Arecoline hydrobromide  |  Oxotremorine M iodide  |  Dronedarone  |  (S)-(+)-Dimethindene maleate  |  Pirenzepine dihydrochloride  |  DREADD agonist 21  |  Benztropine mesylate  |  Darifenacin hydrobromide  |  Tropicamide

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds